2019 Career Support Funds Granted
In 2019, we funded $9.6 million across 20 fellowships, supporting both emerging and established cancer researchers in NSW.
2019 Career Development Fellowships
Career Development Fellowships are for mid-career researchers who demonstrate the potential to undertake research that will have major significance to cancer outcomes.
| Administering Institution | Grantee | Grant Title | Funding (excl. GST) | |
|---|---|---|---|---|
|
The University of Sydney |
Dr Lake-Ee Quek | Exploiting vulnerabilities of prostate cancer lipid metabolism with precision: the use of stable isotope lipidomics to guide treatment strategy |
$455,000 |
|
|
University of New South Wales |
Dr Michelle McDonald |
Tumour-bone cell interactions: An opportunity to harness the microenvironment to overcome metastatic disease |
$599,920 |
|
|
University of New South Wales |
Dr Christine Chaffer |
Manipulating IL-1b/IL-1R1 signalling to inhibit breast cancer metastasis. |
$600,000 |
|
|
University of New South Wales |
Dr Ozren Bogdanovic |
Epigenetic regulation of germline cell fate during oncogenesis |
$410,000 |
|
|
University of New South Wales |
Dr Fatima Valdes Mora |
An epigenetic approach to target akuma-myeloid-derived suppressor cells in breast cancer |
$600,000 |
|
|
University of Newcastle |
Dr Kelly Avery-Kiejda |
Development of a predictive test for p53 and its isoforms to aid the clinical treatment of breast cancer |
$552,460 |
|
|
University of New South Wales |
Dr Mark McCabe |
Non-invasive monitoring of tumour burden and therapeutic response through liquid biopsy and targeted gene capture |
$600,000 |
|
|
University of New South Wales |
Dr George Sharbeen |
A novel multi-cellular therapeutic approach targeting DNA repair in pancreatic cancer |
$150,000 |
|
|
University of Sydney |
Dr Danuta Kalinowski |
An Innovative Pharmacological Approach: The Development of Multi-Targeted Cancer Therapeutics |
$150,000 |
|
|
$4,117,380 |
||||
2019 Early Career Fellowships
Early Career Fellowships are aimed at encouraging researchers to build on their research capability and become leaders of their own research team.
| Administering Institution | Grantee | Grant Title | Funding (excl. GST) | |
|---|---|---|---|---|
|
The University of Sydney |
Dr Emily Blyth |
Development and clinical implementation of adoptive T cell therapies for haematological malignancies |
$480,000 |
|
|
University of New South Wales |
Defining the genomic and epigenetic landscape of high-risk paediatric cancer genomes using long-read sequencing |
$508,231 |
||
|
Cancer Council NSW |
Optimising and Successfully Implementing Cervical Cancer Prevention Policies |
$233,060 |
||
|
University of New South Wales |
Dr Marion Mateos |
Clinical and genomic characteristics associated with symptomatic and severe venous thromboembolism in acute lymphoblastic leukaemia |
$425,673 |
|
|
University of New South Wales |
Dr Matthew Field |
Improving lung cancer outcomes with data-driven prognostic imaging biomarkers in a collaborative medical imaging network |
$420,246 |
|
|
University of New South Wales |
Dr Lin Xiao |
Mechanisms of CBL0137 and Panobinostat Interaction Underlying Their Curative Action in Neuroblastoma |
$592,658 |
|
|
The University of Sydney |
Mr Pascal Steffen |
Investigating the prognostic contribution of immune cell infiltration in rectal cancer |
$600,000 |
|
|
University of New South Wales |
Dr Michael Jameson |
ImproviNg brain cancer ouTcomes with mRi guidEd adaPtIve raDiotherapy (INTREPID) |
$480,000 |
|
|
University of Newcastle |
Dr Danny Lee |
MIRACLE (4D-MRI In Radiotherapy for AChieving tumour Localisation and Effective treatment) |
$548,377 |
|
|
University of Newcastle |
Dr Elizabeth Fradgley |
A multi-component implementation strategy to improve the evidence-based distress management practices of Australian cancer services: the effectiveness and cost of online Training and EducatioNal OutReach visits (The TENOR Trial) |
$597,166 |
|
|
Macquarie University |
Dr Rebeca Sakuma |
Colorectal Cancer Glycobiology: Unexpected Players In Epithelial-Mesenchymal Transition And Inflammation |
$599,997 |
|
|
$5,485,408 |
||||